Dew, from a practical point of view, what does this conversion mean to the minority shareholders? There are now maybe 5-6 million shares in the hands of the minority the rest (?19 million) in the hands of LFB (very rough and approximate numbers based only on memory). If you had to speculate based on the press release and the new corporate presentation (lets see, malaria vaccine--nope, albumin--nope, Alpha 1 antitrypsin--nope, DIC study--nope, Tysabri--nope, undisclosed monoclonal abs--that must be it...) if new stock is to be issued (horrible thought) or maybe they have finally got enough partnership support to go forward, what that might mean for the minority shareholders? In essence the "float" is 6-7 million on the market unless LFB sells some of their shares which is unlikely. GTC is talking like an independent company regarding positive cash flow in 2+ years. Its all been such a disaster, but penny stock inverstors might finally have something to look at. Would that I had just discovered this stock yesterday and not 15 years ago. With so few shares in the hands of the minority stock holders, a benificent LFB could buy the company for say 50--100 (I just dropped that number in there as a suggestion to LFB) million with little complaint from the minority. Could it be that they (GTC), "still believe" and are holding on? It certainly is not so from an insider buyer standpoint, (never has been). They seem to have drawn a breath from the biobetter, biosimiliar legislation. What would you speculate now after this new press release? bp
